Sort
48,018 grants matching “immunotherapy”
Developing isoform-selective Hsp90 inhibitors for monotherapy and enhanced immunotherapy against lethal prostate cancer
$551,601Brian S J Blagg · University Of Notre Dame · R01 · FY2025 · CA
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients
$551,600James M Markert · University Of Alabama At Birmingham · R01 · FY2020 · CA
Nanodelivery platform for antibody drugs targeting NHL
$551,578Masakazu Kamata · University Of California Los Angeles · R01 · FY2018 · CA
Program stem-like CD8 T cells to enhance antiviral immunity against chronic viral infection
$551,568Tuoqi Wu · Ut Southwestern Medical Center · R01 · FY2022 · AI
Understanding the functional agility of effector memory CD8 T cells
$551,436Sara Elizabeth Hamilton Hart · University Of Minnesota · R01 · FY2024 · AI
Understanding the functional agility of effector memory CD8 T cells
$551,436Sara Elizabeth Hamilton Hart · University Of Minnesota · R01 · FY2023 · AI
Understanding the functional agility of effector memory CD8 T cells
$551,436Sara Elizabeth Hamilton Hart · University Of Minnesota · R01 · FY2021 · AI
Understanding the functional agility of effector memory CD8 T cells
$551,436Sara Elizabeth Hamilton Hart · University Of Minnesota · R01 · FY2025 · AI
Understanding the functional agility of effector memory CD8 T cells
$551,436Sara Elizabeth Hamilton Hart · University Of Minnesota · R01 · FY2022 · AI
Developmental Funds
$551,431Steven K. Libutti · Rbhs -Cancer Institute Of New Jersey · P30 · FY2019 · CA
Whitlockite nanoparticle-based immunotherapy for bone metastasis
$551,431Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2020 · CA
FETAL IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS
$551,429Dana-Farber Cancer Institute · R01 · FY2000 · AI
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC
$551,399Ralf Kittler · Ut Southwestern Medical Center · R01 · FY2025 · CA
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC
$551,399Ralf Kittler · Ut Southwestern Medical Center · R01 · FY2023 · CA
Response and Acquired Resistance to PD-1 Blockade
$551,291Antoni Ribas · University Of California Los Angeles · R01 · FY2015 · CA
Deployable Ultrasound Applicators for MRI Guided Thermal Therapy of Pancreatic Cancer
$551,271Chris John Diederich · University Of California, San Francisco · R01 · FY2019 · EB
Mechanisms of increased susceptibility to TB in HIV-Infected individuals
$551,240David H Canaday · Case Western Reserve University · R01 · FY2012 · AI
Overcoming obesity-associated immunotherapy resistance in renal cancer
$551,148Lyse A Norian · University Of Alabama At Birmingham · R01 · FY2023 · CA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer
$551,141Kevin Finnbar Staveleyo'carroll · University Of Missouri-Columbia · R01 · FY2019 · CA
Determining how a Werner helicase (WRN) tumor suppressor complex regulates the human papillomavirus 16 life cycle
$551,093Iain Morgan · Virginia Commonwealth University · R01 · FY2022 · DE
Innate lymphoid cell regulation of the host-microbiota interactions in cancer
$551,090Gregory F Sonnenberg · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
$551,067John V. Heymach · University Of Tx Md Anderson Can Ctr · U01 · FY2021 · CA
Cell type-directed Tim-3 targeting in melanoma
$551,025Steven Russell Barthel · Brigham And Women'S Hospital · R01 · FY2024 · CA
Boosting anti-HIV immunity through manipulation of Tfh function.
$551,007Elias K Haddad · Drexel University · R01 · FY2016 · AI
Boosting anti-HIV immunity through manipulation of Tfh function.
$551,007Elias K Haddad · Drexel University · R01 · FY2015 · AI